Filing Flows › Korsana Biosciences (KRSA) › Q4 2025
Korsana Biosciences (KRSA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 30, 2026
Korsana Biosciences (KRSA) reported revenue of $1.0M for the fourth quarter 2025 (Q4 2025), -43% from a year earlier and +17% from the quarter before. Operating margin was -81.8%, net loss $799K (78.0% of revenue).
Korsana Biosciences, Q4 2025: revenue $1.0M (-43% year over year), operating margin -81.8%, net loss $799K, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | +17% | -43% |
| Operating profit | −$838K | — | -267% |
| Net earnings | −$799K | — | -251% |
| Operating cash flow | −$1.6M | — | -539% |
What changed
Revenue was $1.0M in Q4 2025, down 43% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $838K, an operating margin of -81.8%. Total costs grew 43% against a revenue fall of 43%. The fastest-growing cost line was Research & development (+827%). The quarter ended with a net loss of $799K, narrower than the previous quarter's $1.0M loss.
Operating cash flow was −$1.6M. Non-cash charges added back $95K of share-based compensation. Working capital and other items used $875K.
Questions
What was Korsana Biosciences' revenue in the fourth quarter 2025?
Korsana Biosciences (KRSA) reported revenue of $1.0M for the fourth quarter 2025 (Q4 2025), -43% from a year earlier and +17% from the quarter before.
Was Korsana Biosciences profitable in the fourth quarter 2025?
Operating loss was $838K (-81.8% of revenue) and net loss $799K.